Aug 20, 2022 02:23 AM

BUSINESS

Pfizer Signs China Partnership to Make Paxlovid Covid Pills Locally

By Qi Zhanning and Han Wei

Approved in the U.S. for emergency use, Paxlovid has been cleared for Covid-19 treatment in 70 countries and regions globally.

Approved in the U.S. for emergency use, Paxlovid has been cleared for Covid-19 treatment in 70 countries and regions globally.

Chinese drugmaker Zhejiang Huahai Pharmaceutical Co. Ltd. has entered an agreement with Pfizer Inc. to manufacture the U.S. giant’s Covid-19 pill Paxlovid in China.

Shanghai-listed Huahai Pharmaceutical said Thursday that it has signed a non-exclusive production and supply agreement with the Chinese subsidiary of Pfizer. Under the agreement, Huahai Pharmaceutical will produce Paxlovid in China for five years.

You've accessed an article available only to subscribers

Subscribe today for just $.99.

VIEW OPTIONS

Share this article

Open WeChat and scan the QR code

GALLERY

: Gallery: China Celebrates Golden Week

NEWSLETTERS

Get our CX Daily, weekly Must-Read and China Green Bulletin newsletters delivered free to your inbox, bringing you China's top headlines.

We ‘ve added you to our subscriber list.

Manage subscription

PODCAST

Caixin Deep Dive: Why Singapore Sovereign Fund Sues Chinese EV-Maker Nio

00:00

00:00/00:00

MOST POPULAR

1: Cover Story: U.S. and Chinese Chipmakers Tread Different Paths in AI Gold Rush

2: Shenzhen’s Secondhand Home Sales Briefly Rebound in September After Easing of Purchase Restrictions

3: Xiaomi, EV Rivals Offer Tax Subsidies Ahead of China’s 2026 Incentive Cut

4: China’s MetaX Wins IPO Nod as AI Chipmakers Race to Go Public

5: In Depth: Chip Foundries Kick Off State-Backed Consolidation Drive

SPONSORED

OR